MarketInOut Stock Screener Log In | Sign Up
 

Adagene Inc ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 09/25/2026
Adagene Inc ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization200.09 mln
Float57.15 mln
Earnings Date03/31/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

61.93
Highly suspicious

1-Year Forecast

9.91
Transformational upside

Relative Strength

8 / 100
Severely lagging

Debt / Equity

0.07
Debt-free

Pre-Tax Margin

-225%
Severely loss-making

Business Description

Adagene is a China-based biotechnology company focused on developing antibody-based treatments for cancer. Founded in 2011 and headquartered in Suzhou, the company has built a broad pipeline of drug candidates at various stages of clinical testing, targeting both solid tumors and blood cancers. Its portfolio includes several antibody therapies designed to improve how the immune system attacks cancer cells, with some already in mid-stage clinical trials and others still in early research.

Key Fundamentals

EPS-0.37
ROE-37.82
RPS0.18
ROIC-242
ROA-22.11
Interest Cover-78.34
EBITDA, mln-20.05
EV / EBITDA-6.21
EV / EBIT-6.05
Revenue, mln9.29
EV / Revenue13.41

Quote Details

Last 2.93
Change -0.05 (-1.68%)
Open 2.96
Volume 196,885
Turnover 576,873
Average Volume 219,147

Financial Ratios

Pre-Tax Profit Margin-225
Leverage Ratio1.26
Current Ratio5.02
Price / Book2.76
Price / Tangible Book2.76
Debt / Equity0.07
Price / Sales19.21

Financial Strength

Altman Z-Score-2.27
Piotroski F-Score 4 / 9
Beneish M-Score61.93
1-Year Target Price9.91
Short Ratio8.13
Short % of Float3.63

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -11.48% 6 / 100   
1 Month -23.9% 8 / 100   
2 Months -25.63% 16 / 100   
6 Months -29.23% 14 / 100   
1 Year 44.33% 89 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us